Humanized anti-beta7 antagonists and uses therefor

Abstract

The invention provides therapeutic anti-beta7 antibodies, compositions comprising, and methods of using these antibodies.

What is claimed is: 
     
         1 - 53 . (canceled) 
     
     
         54 . An anti-beta7 antibody comprising:
 an HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2 and HVR-H3, wherein each, in order, comprises RASESVDDLLH (SEQ ID NO:9), KYASQSIS (SEQ ID NO:2), QQGNSLPNT (SEQ ID NO:3), GFFITNNYWG (SEQ ID NO:4), GYISYSGSTSYNPSLKS (SEQ ID NO:5), and RTGSSGYFDF (SEQ ID NO:66).   
     
     
         55 - 60 . (canceled) 
     
     
         61 . A method of inhibiting the interaction of a human beta7 integrin subunit with a second integrin subunit and/or a ligand by contacting a humanized anti-beta7 antibody with the beta7 integrin. 
     
     
         62 . The method of  claim 61 , wherein the anti-beta7 antibody comprises an HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2 and HVR-H3, wherein each, in order, comprises RASESVDDLLH (SEQ ID NO:9), KYASQSIS (SEQ ID NO:2), QQGNSLPNT (SEQ ID NO:3), GFFITNNYWG (SEQ ID NO:4), GYISYSGSTSYNPSLKS (SEQ ID NO:5), and RTGSSGYFDF (SEQ ID NO:66). 
     
     
         63 . A method of modulating beta7 integrin-mediated cellular adhesion and/or recruitment in a human experiencing a disorder by administering to the mammal an effective amount of a composition comprising a humanized anti-beta7 antibody and a pharmaceutical carrier. 
     
     
         64 . The method of  claim 63 , wherein the anti-beta7 antibody comprises an HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2 and HVR-H3, wherein each, in order, comprises RASESVDDLLH (SEQ ID NO:9), KYASQSIS (SEQ ID NO:2), QQGNSLPNT (SEQ ID NO:3), GFFITNNYWG (SEQ ID NO:4), GYISYSGSTSYNPSLKS (SEQ ID NO:5), and RTGSSGYFDF (SEQ ID NO:66).